Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1012889 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Bang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Phlebovirus, Antibodies, Neutralizing, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province of China, Nanjing Important Science & Technology Specific Projects.
Abstract (Originalsprache)
Severe fever with thrombocytopenia syndrome (SFTS) is a viral hemorrhagic fever caused by a tick-borne virus SFTSV with a mortality rate of up to 30%. Currently, there is no vaccine or effective therapy for SFTS. Neutralizing monoclonal antibody therapy, which provides immediate passive immunity and may limit disease progression, has emerged as a reliable approach for developing therapeutic drugs for SFTS. In this study, 4 human monoclonal antibodies (hmAbs) derived from convalescent SFTS patients’ lymphocytes based on human single-chain variable fragment antibody libraries were tested for their neutralizing activities in cells and their treatment effect in animals individually and in pair combinations. The neutralization test showed that all 4 hmAbs exhibited strong neutralizing activity against SFTSV infection in vitro . The protection rate of hmAbs 4-6, 1F6, 1B2, and 4-5 against SFTSV lethal challenge in IFNAR1 -/- A129 mice are 50%, 16.7%, 83.3%, and 66.7%, respectively. Notably, the pair combination of antibodies (1B2 and 4-5, 1B2 and 1F6) that recognized distinct epitopes protected 100% of mice against SFTSV lethal challenge. In conclusion, our findings indicate that the pair combinations of hmAbs 1B2 and 4-5 or hmAbs 1B2 and 1F6 may serve as promising therapeutic drugs for treating SFTSV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, China.
- Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China.
- Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Institute of Pathogenic Microbiology, Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China.
ORCID-Profile: Xue-Jie Yu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province of China
- Nanjing Important Science & Technology Specific Projects
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, B., Qin, X. R., Qu, J. C., Wu, G. D., Zhang, W. K., Jiang, Z. Z., Liu, P. P., Li, Z. M., Yu, T. M., Zhou, C. M., Jiao, Y. J., & Yu, X. J. (2025). Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012889
Vancouver
Li B, Qin XR, Qu JC, Wu GD, Zhang WK, Jiang ZZ, et al. Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1012889
BibTeX
@article{Li2025,
author = {Li, Bang and Qin, Xiang-Rong and Qu, Jia-Chen and Wu, Guan-du and Zhang, Wen-Kang and Jiang, Ze-Zheng and Liu, Pan-Pan and Li, Ze-Min and Yu, Tian-Mei and Zhou, Chuan-Min and Jiao, Yong-Jun and Yu, Xue-Jie},
title = {Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1012889}
}
EUVIMED